Eli Lilly and Novo Nordisk have agreed pricing deals for GLP-1RA brands, a pivotal moment in the obesity treatment market.

Editor's note: this interview was originally published on BioPharmInternational.com.

Q3 2025 Management View CEO Stephen Silvestro reported a strong third quarter with revenues increasing 22% year-over-year to ...

Abzena and Mabqi have announced a partnership integrating antibody discovery capabilities with development and manufacturing ...

Q3 2025 Earnings Call November 6, 2025 4:30 PM ESTCompany ParticipantsStephen Silvestro - President & CEOEdward Stelmakh ...

Market opportunities lie in modernizing software development and validation approaches, emphasizing agility and continuous validation to meet changing needs, while ensuring compliance with FDA ...

Sonoma Pharmaceuticals Inc. (Nasdaq: SNOA) reported record revenue and a lower net loss for the second quarter of its fiscal year.

The US Food and Drug Administration-approved Marie system promises human-centred care, advanced technology and lower costs.

Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced its successful participation in the ...

The robust 77.8% three-month CR rate observed in the UTOPIA trial is highly encouraging and reinforces the potential of UGN-103 to deliver meaningful benefits to patients,” said Liz Barrett, President ...

Standard Glass Lining Technology Limited Announces Strong Q2 FY26 Performance and Strategic Transformation into a High- Precision Engineering Powerhouse ...

Discover key insights from McKesson’s Q2 2026 earnings call, including record growth, raised guidance, and strategic investments.